Leritrelvir

Leritrelvir
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (3S,3aS,6aR)-2-[(2S)-2-cyclohexyl-2-[(2,2,2-trifluoroacetyl)amino]acetyl]-N-[(2S)-4-(cyclopentylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-3-carboxamide;
CAS Number	2923310-64-7;
PubChem CID	167713195;
ChemSpider	128922060;
ChEMBL	ChEMBL5422898;
Chemical and physical data
Formula	C31H44F3N5O6
Molar mass	639.717 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)[C@@H](C(=O)N2C[C@@H]3CCC[C@@H]3[C@H]2C(=O)N[C@@H](C[C@@H]4CCNC4=O)C(=O)C(=O)NC5CCCC5)NC(=O)C(F)(F)F;
	InChI InChI=1S/C31H44F3N5O6/c32-31(33,34)30(45)38-23(17-7-2-1-3-8-17)29(44)39-16-19-9-6-12-21(19)24(39)27(42)37-22(15-18-13-14-35-26(18)41)25(40)28(43)36-20-10-4-5-11-20/h17-24H,1-16H2,(H,35,41)(H,36,43)(H,37,42)(H,38,45)/t18-,19-,21-,22-,23-,24-/m0/s1; Key:ICGMMLTUQDVAST-HEZDJTGRSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Leritrelvir (RAY1216) is an antiviral drug which acts as a 3C-like protease inhibitor. It was developed and approved^[1] in China for treatment of COVID-19.^[2]^[3]^[4]^[5]

References

^ Zheng L, Wang W, Sun Q (2024). "Targeted drug approvals in 2023: Breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy. 9 (1): 46. doi:10.1038/s41392-024-01770-y. PMC 10879080. PMID 38378623.
^ Janin YL (January 2024). "On the origins of SARS-CoV-2 main protease inhibitors". RSC Medicinal Chemistry. 15 (1): 81–118. doi:10.1039/d3md00493g. PMC 10809347. PMID 38283212.
^ Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, et al. (September 2024). "Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics". Acta Pharmaceutica Sinica. B. 14 (9): 4028–4044. doi:10.1016/j.apsb.2024.05.026. PMC 11413674. PMID 39309487.
^ Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, et al. (December 2023). "Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116)". Frontiers of Medicine. 17 (6): 1068–1079. doi:10.1007/s11684-023-1037-3. PMID 38165534.
^ Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, et al. (March 2024). "Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis". International Journal of Antimicrobial Agents. 63 (3): 107096. doi:10.1016/j.ijantimicag.2024.107096. PMID 38244811.

[1] Zheng L, Wang W, Sun Q (2024). "Targeted drug approvals in 2023: Breakthroughs by the FDA and NMPA". Signal Transduction and Targeted Therapy. 9 (1): 46. doi:10.1038/s41392-024-01770-y. PMC 10879080. PMID 38378623.

[2] Janin YL (January 2024). "On the origins of SARS-CoV-2 main protease inhibitors". RSC Medicinal Chemistry. 15 (1): 81–118. doi:10.1039/d3md00493g. PMC 10809347. PMID 38283212.

[3] Chan CC, Guo Q, Chan JF, Tang K, Cai JP, Chik KK, et al. (September 2024). "Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics". Acta Pharmaceutica Sinica. B. 14 (9): 4028–4044. doi:10.1016/j.apsb.2024.05.026. PMC 11413674. PMID 39309487.

[4] Cao Q, Ding Y, Xu Y, Li M, Zheng R, Cao Z, et al. (December 2023). "Small-molecule anti-COVID-19 drugs and a focus on China's homegrown mindeudesivir (VV116)". Frontiers of Medicine. 17 (6): 1068–1079. doi:10.1007/s11684-023-1037-3. PMID 38165534.

[5] Zheng B, Zhao Q, Yang W, Feng P, Xin C, Ying Y, et al. (March 2024). "Small-molecule antiviral treatments for COVID-19: A systematic review and network meta-analysis". International Journal of Antimicrobial Agents. 63 (3): 107096. doi:10.1016/j.ijantimicag.2024.107096. PMID 38244811.

[1]

[2]

[3]

[4]

[5]